(Q50243911)

28 February 2018

title

A metal-based inhibitor of tumor necrosis factor-α. (English)

1 reference

28 February 2018

Victor Pui-Yan Ma

6

0 references

Dik-Lung Ma

object named as

Dik-Lung Ma

9

0 references

Chung-Hang Leung

1

object named as

Chung-Hang Leung

1 reference

28 February 2018

Hai-Jing Zhong

2

1 reference

28 February 2018

Hui Yang

3

1 reference

28 February 2018

Zhen Cheng

4

1 reference

28 February 2018

Daniel Shiu-Hin Chan

5

1 reference

28 February 2018

Ruben Abagyan

7

1 reference

28 February 2018

Chun-Yuen Wong

8

1 reference

28 February 2018

language of work or name

English

0 references

publication date

13 July 2012

1 reference

28 February 2018

Angewandte Chemie International Edition

published in

0 references

volume

51

1 reference

28 February 2018

issue

36

1 reference

28 February 2018

page(s)

9010-9014

1 reference

28 February 2018

Tumor necrosis factor signaling.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Signalling pathways of the TNF superfamily: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Anti-TNF-alpha antibody therapies in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Anti-TNF-alpha therapies: the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Inhibition of tumor necrosis factor-alpha (TNF-alpha)/TNF-alpha receptor binding by structural analogues of suramin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Small-molecule inhibition of TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

A new three-component reaction: green synthesis of novel isoindolo[2,1-a]quinazoline derivatives as potent inhibitors of TNF-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

A natural product-like inhibitor of NEDD8-activating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Structure-based discovery of natural-product-like TNF-α inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Developing new metal-based therapeutics: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Metal based drugs: from serendipity to design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

New trends for metal complexes with anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Recent developments in ruthenium anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Bioorganometallic chemistry--from teaching paradigms to medicinal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Platinum drug distribution in cancer cells and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Metal complexes as DNA intercalators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Iridium complex with antiangiogenic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Structurally Sophisticated Octahedral Metal Complexes as Highly Selective Protein Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Targeting proteins with metal complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Exploring biologically relevant chemical space with metal complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201202937

21 January 2018

Identifiers

DOI

10.1002/ANIE.201202937

1 reference

28 February 2018

1 reference

28 February 2018